UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.06.25 | Market Closed - BOERSE MUENCHEN 01:12:07 25/05/2024 am IST | ||
| 2.93 EUR | +8.12% |
|
| Current month | +125.38% | ||
| 1 month | +84.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 2.93 | +8.12% |
| 23/24/23 | 2.71 | +5.04% |
| 22/24/22 | 2.58 | +7.05% |
| 21/24/21 | 2.41 | -7.66% |
| 20/24/20 | 2.61 | +1.95% |
Real-time BOERSE MUENCHEN
Last update May 25, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC7U37 |
| ISIN | DE000HC7U375 |
| Date issued | 30/06/2023 |
| Strike | 550 $ |
| Maturity | 18/06/2025 (389 Days) |
| Parity | 10 : 1 |
| Emission price | 2.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.95 € |
|---|---|
| Lowest since issue | 1.09 € |
| Spread | 0.03 € |
| Spread % | 1.01% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
